Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer

Giampaolo Bianchini • 15 Sep 2020
ESMO 2020
Breast Cancer Antibodies Atezolizumab Carboplatin Nab-paclitaxel
NeoTRIPaPDL1

Giampaolo Bianchini, MD, of IRCCS San Raffaele Hospital, Milan, Italy, discusses data coming from the NeoTRIPaPDL1 trial (NCT02620280) – a randomized Phase III study evaluating neoadjuvant atezolizumab with carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. The data presented at ESMO 2020 looked at the role of tumour infiltrating lymphocytes (TILs) and PD-L1 expression in samples collected at baseline, Day 1 of cycle 2 or at surgery. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giampaolo Bianchini

4:10
BioltaLEE: ctDNA dynamics in HR+/HER2- advanced breast cancer
Giampaolo Bianchini • 8 Dec 2021
3:07
Single-cell spatial analysis in TNBC from NeoTRIPaPDL1
Giampaolo Bianchini • 8 Dec 2021
2:31
COVID-19 related personalized risk-benefit ratio adaptation of breast cancer care
Giampaolo Bianchini • 15 Sep 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals